Visus Therapeutics lands $20M to develop eye drop that corrects vision loss
Visus Therapeutics, a Seattle-based startup developing a presbyopia-correcting eye drop, raised $20 million. The fresh cash comes just six months after the company raised $36 million. Backers in this round include LSP, Sage Partners, Johnson & Johnson Innovation, and others. The companyâ€™s lead asset, BRIMOCHOL, is a once-daily eye drop that aims to treat presbyopia, a vision condition caused by aging that can make tasks such as reading difficult. Founded in 2019, Visus is led by CEO Ben Bergo, who previously co-founded Lumos Diagnostics and Seattle-based Nohla Therapeutics.